Iovance Biotherapeutics
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 557
- Market Cap
- $3.4B
- Website
- http://www.iovance.com
- Introduction
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
Clinical Trials
35
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (34 trials with phase data)β’ Click on a phase to view related trials
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
- Conditions
- Unresectable MelanomaMetastatic MelanomaOcular Melanoma
- Interventions
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT06940739
- Locations
- πΊπΈ
SCRI Oncology Partners- Denver, Denver, Colorado, United States
πΊπΈSarah Cannon Research Institute, Nashville, Tennessee, United States
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
- Conditions
- RhabdomyosarcomaSoft Tissue SarcomaEwing SarcomaPrimary Central Nervous System CarcinomaMelanoma
- Interventions
- Biological: LN-145/LN-144
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06566092
- Locations
- πΊπΈ
Children's Hospital of Colorado, Aurora, Colorado, United States
πΊπΈRoswell Park Cancer Institute, Buffalo, New York, United States
πΊπΈJohns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2025-10-30
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06481592
- Locations
- πΊπΈ
Honor Health, Phoenix, Arizona, United States
πΊπΈAugusta University, Augusta, Georgia, United States
πΊπΈUniversity of Southern California, Los Angeles, California, United States
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
- Conditions
- MelanomaUnresectable MelanomaMetastatic Melanoma
- Interventions
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 670
- Registration Number
- NCT05727904
- Locations
- πΊπΈ
University of Alabama at Birmingham: The Kirklin Clinic, Birmingham, Alabama, United States
πΊπΈCity of Hope, Duarte, California, United States
πΊπΈUSC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release
- Conditions
- Unresectable MelanomaMetastatic Melanoma
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Registration Number
- NCT05398640
- Locations
- πΊπΈ
HonorHealth, Scottsdale, Arizona, United States
πΊπΈCity of Hope, Duarte, California, United States
πΊπΈStanford Hospital, Stanford, California, United States
- Prev
- 1
- 2
- 3
- Next
News
Iovance Reports Promising 26% Response Rate for Lifileucel TIL Therapy in Advanced NSCLC
Iovance Biotherapeutics announced interim data from its Phase 2 IOV-LUN-202 trial showing lifileucel achieved a 25.6% objective response rate in previously treated advanced nonsquamous NSCLC patients.
Lifileucel TIL Therapy Shows Disease Stabilization in Advanced Head and Neck Cancer Patients
A phase II trial of lifileucel autologous tumor-infiltrating lymphocyte therapy demonstrated feasibility and disease stability in 53 patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Health Canada Approves Iovance's AMTAGVI as First T-Cell Therapy for Solid Tumors in Canada
Health Canada granted conditional marketing authorization for AMTAGVI, marking the first T-cell therapy approved for solid tumors in Canada, specifically for advanced melanoma treatment.
Tumor-Infiltrating Lymphocyte Therapy Market Poised for Explosive Growth Following First FDA Approval
The tumor-infiltrating lymphocyte (TIL) therapy market is transitioning from experimental to commercial use following the FDA approval of Iovance Biotherapeutics' AMTAGVI for advanced melanoma in 2024.
Iovance Biotherapeutics Withdraws Amtagvi EU Filing, Stock Plunges 29% Despite Strong Q2 Sales
Iovance Biotherapeutics voluntarily withdrew its European Union regulatory filing for Amtagvi due to lack of alignment with the EMA on clinical data supporting the submission.
Iovance Biotherapeutics Implements Major Restructuring Amid Regulatory Setbacks and Commercial Challenges
Iovance Biotherapeutics reduced its workforce by 19% in Q3 2025 and targets $100 million in annual savings to extend cash runway to late 2026.
Iovance Reports Strong Q2 2025 Results with $60M Revenue as Amtagvi Adoption Accelerates
Iovance Biotherapeutics achieved $60.0 million in total product revenue for Q2 2025, representing a 93% year-over-year increase driven by strong Amtagvi adoption.
Iovance Biotherapeutics Cuts Workforce by Nearly 20% Following Slow Amtagvi Cell Therapy Launch
Iovance Biotherapeutics is reducing its workforce by less than 20% in a strategic restructuring following disappointing commercial performance of its TIL cell therapy Amtagvi.
Iovance Biotherapeutics Shares Surge 14% on Amtagvi FDA Approval and New CEO Appointment
Iovance Biotherapeutics shares surged 14.46% in pre-market trading following FDA approval of its cancer treatment Amtagvi and positive clinical trial results.
Iovance Biotherapeutics Expands Workforce with Stock Option Grants for New Employees
Iovance Biotherapeutics granted stock options covering 320,560 shares to 40 new employees across two separate announcements in July and August 2025.